Kymera Therapeutics Reveals Preclinical Data on Cancer-Fighting Drug KT-333 at AACR Meeting
Kymera Therapeutics Reveals Preclinical Data on Cancer-Fighting Drug KT-333 at AACR Meeting
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new preclinical data showing the structural and molecular mechanisms underlying anti-tumor activity of its novel STAT3 degrader, KT-333, were presented in a late-breaking research poster session at the AACR Annual Meeting taking place April 5-10, 2024, in San Diego, California. Additionally, Nello Mainolfi, PhD, Founder, President and CEO, will present in the Major Symposium at the conference highlighting the Company's unique target selection strategy and strong preclinical to clinical translation observed across the Company's first-in-class oncology programs, KT-333 and KT-253, a potent and selective degrader of MDM2.
Kymera Therapeutics, Inc.（纳斯达克股票代码：KYMR）是一家临床阶段的生物制药公司，正在推进使用靶向蛋白质降解（TPD）的新型小分子药物。该公司今天宣布，在2024年4月5日至10日在圣地亚哥举行的AACR年会的最新研究海报发布会上公布了显示其新型 STAT3 降解剂 KT-333 抗肿瘤活性的结构和分子机制的新临床前数据，加利福尼亚州。此外，创始人、总裁兼首席执行官Nello Mainolfi博士将在会议上的主要研讨会上发表演讲，重点介绍公司独特的靶点选择策略以及在公司首创的肿瘤项目 KT-333 和 KT-253（一种强效的选择性MDM2降解剂）中观察到的强大的临床前到临床转化。
译文内容由第三方软件翻译。